Susan Dent MD FRCPC
@susandent.bsky.social
Medical Oncologist /Cardio-Oncologist
Wilmot Cancer Institute
Professor of Medicine, University of Rochester
Director of the Judy DiMarzo Survivorship program
Director of Cardio-Oncology
Rochester, New York
President International Cardio-Oncology Society
Wilmot Cancer Institute
Professor of Medicine, University of Rochester
Director of the Judy DiMarzo Survivorship program
Director of Cardio-Oncology
Rochester, New York
President International Cardio-Oncology Society
Pinned
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer
The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial…
www.sciencedirect.com
www.sciencedirect.com/science/arti...
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!
It is so important to understand how cancer treatments impact cardiovascular health!
On this episode of #HeartToHeart, we're joined by @itsnotpink.bsky.social of @graspcancer.bsky.social.
Julia shares her treatment journey with IC-OS President @susandent.bsky.social and treating physician Ana Barac, MD.
Tune In: tinyurl.com/bpju4ec4
Julia shares her treatment journey with IC-OS President @susandent.bsky.social and treating physician Ana Barac, MD.
Tune In: tinyurl.com/bpju4ec4
May 19, 2025 at 4:51 PM
It is so important to understand how cancer treatments impact cardiovascular health!
Reposted by Susan Dent MD FRCPC
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer - Apr 17, 2025
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
April 25, 2025 at 8:36 PM
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer - Apr 17, 2025
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
Reposted by Susan Dent MD FRCPC
Cardio-Oncology screening program ensures timely referrals for cardiotoxicity #oncologynursing #ONS50 #ONSCongress
www.oncologynurseadvisor.com/reports/canc...
www.oncologynurseadvisor.com/reports/canc...
Cardio-Oncology Screening Program Ensures Timely Referrals for Cardiotoxicity - Oncology Nurse Advisor
Screening program provides timely referrals to patients with cancer for management of potential cardiotoxicities.
www.oncologynurseadvisor.com
April 17, 2025 at 7:19 PM
Cardio-Oncology screening program ensures timely referrals for cardiotoxicity #oncologynursing #ONS50 #ONSCongress
www.oncologynurseadvisor.com/reports/canc...
www.oncologynurseadvisor.com/reports/canc...
Reposted by Susan Dent MD FRCPC
I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation
April 16, 2025 at 10:29 PM
I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation
Reposted by Susan Dent MD FRCPC
Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
April 15, 2025 at 7:31 PM
Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
Reposted by Susan Dent MD FRCPC
In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42
Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor
(ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those
with ER-low BC (ER 1%-10%)...
ascopubs.org
April 13, 2025 at 12:44 PM
In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42
Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Reposted by Susan Dent MD FRCPC
Congratulations to the University of Rochester for being named the 73rd NCI designated Cancer Center!!!!
March 18, 2025 at 6:05 PM
Congratulations to the University of Rochester for being named the 73rd NCI designated Cancer Center!!!!
Reposted by Susan Dent MD FRCPC
Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...
March 18, 2025 at 1:52 AM
Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...
On International Women’s Day spending time with this amazing group of women who provide flying fishing retreats for breast cancer survivors!
March 8, 2025 at 6:01 PM
On International Women’s Day spending time with this amazing group of women who provide flying fishing retreats for breast cancer survivors!
Important to consider comorbidities when selecting first line therapy in HR+HER2- metastatic breast cancer !
January 27, 2025 at 12:02 PM
Important to consider comorbidities when selecting first line therapy in HR+HER2- metastatic breast cancer !
Dear colleagues. We have an exciting opportunity for a breast cancer medical oncologist in Rochester New York! If you are interested in leading a dynamic clinical research program let me know. Come and join a growing team while enjoying the wonderful nature of upper state New York!
January 25, 2025 at 5:54 PM
Dear colleagues. We have an exciting opportunity for a breast cancer medical oncologist in Rochester New York! If you are interested in leading a dynamic clinical research program let me know. Come and join a growing team while enjoying the wonderful nature of upper state New York!
Reposted by Susan Dent MD FRCPC
Interesting endpoint and trial.
Few MBC patients treated and very small.
For oligoprogressive cancer,
SBRT could delay time to systemic therapy change.
This could could valuable for the right patient trying to delay time to chemotherapy.
www.redjournal.org/article/S036...
Few MBC patients treated and very small.
For oligoprogressive cancer,
SBRT could delay time to systemic therapy change.
This could could valuable for the right patient trying to delay time to chemotherapy.
www.redjournal.org/article/S036...
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial
In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing
on a background of stable or responding to widespread cancer. Although the standard
of care for OP is changi...
www.redjournal.org
January 19, 2025 at 10:38 PM
Interesting endpoint and trial.
Few MBC patients treated and very small.
For oligoprogressive cancer,
SBRT could delay time to systemic therapy change.
This could could valuable for the right patient trying to delay time to chemotherapy.
www.redjournal.org/article/S036...
Few MBC patients treated and very small.
For oligoprogressive cancer,
SBRT could delay time to systemic therapy change.
This could could valuable for the right patient trying to delay time to chemotherapy.
www.redjournal.org/article/S036...
Reposted by Susan Dent MD FRCPC
🆕
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social
thelancet.com/journals/lanon…
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social
thelancet.com/journals/lanon…
January 3, 2025 at 4:08 PM
🆕
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social
thelancet.com/journals/lanon…
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social
thelancet.com/journals/lanon…
Reposted by Susan Dent MD FRCPC
What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Concomitant intake of proton pump inhibitors (PPIs) may create drug–drug interactions, potentially impacting efficacy of anticancer agents. In the pha…
www.sciencedirect.com
January 3, 2025 at 6:46 PM
What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Can PPI use explain why the PALLAS trial was negative?
Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Reposted by Susan Dent MD FRCPC
Happy new year to all
December 30, 2024 at 6:45 PM
Happy new year to all
77510762.flowpaper.com/ICOS2024News...
Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!
Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!
IC-OS 2024 Newsletter
77510762.flowpaper.com
December 23, 2024 at 10:15 PM
77510762.flowpaper.com/ICOS2024News...
Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!
Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!
Reposted by Susan Dent MD FRCPC
3. Insurance profits outpace health care spending
December 20, 2024 at 4:37 PM
3. Insurance profits outpace health care spending
Reposted by Susan Dent MD FRCPC
Survivorship means different things to different individuals. One of which remains how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines to ensure equitable & comprehensive care #oncsky #oncologynursing
jnccn.org/view/journal...
jnccn.org/view/journal...
jnccn.org
December 19, 2024 at 7:28 PM
Survivorship means different things to different individuals. One of which remains how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines to ensure equitable & comprehensive care #oncsky #oncologynursing
jnccn.org/view/journal...
jnccn.org/view/journal...
Reposted by Susan Dent MD FRCPC
📣Abstract deadline for St. Gallen’s Breast Cancer Consensus Conf extended!! The top 5️⃣ posters present in front of global leaders. 🌍 [plus you’ll join me in beautiful Vienna 🇦🇹]
Final deadline: Jan 5, 2025
🔗 sgbcc2025.abstractserver.com/submission/#...
#oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social
Final deadline: Jan 5, 2025
🔗 sgbcc2025.abstractserver.com/submission/#...
#oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social
December 19, 2024 at 8:15 PM
📣Abstract deadline for St. Gallen’s Breast Cancer Consensus Conf extended!! The top 5️⃣ posters present in front of global leaders. 🌍 [plus you’ll join me in beautiful Vienna 🇦🇹]
Final deadline: Jan 5, 2025
🔗 sgbcc2025.abstractserver.com/submission/#...
#oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social
Final deadline: Jan 5, 2025
🔗 sgbcc2025.abstractserver.com/submission/#...
#oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social
Reposted by Susan Dent MD FRCPC
Bravo Kate! Thank you for your leadership and commitment to children everywhere.
National Association of School Nurses President, Dr. Kate King was on CNN yesterday to talk about the importance of vaccinations and the role of school nurses in promoting vaccine confidence! Great job, Kate!
app.frame.io/presentation...
app.frame.io/presentation...
December 19, 2024 at 8:17 AM
Bravo Kate! Thank you for your leadership and commitment to children everywhere.
Reposted by Susan Dent MD FRCPC
December 16, 2024 at 11:09 PM
Reposted by Susan Dent MD FRCPC
Prostate Cancer Therapy Cardiotoxicity Map:
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
December 16, 2024 at 9:28 PM
Prostate Cancer Therapy Cardiotoxicity Map:
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC.
#ProstateCancer #Oncology
@oncoalert.bsky.social
@oncbrothers.bsky.social
Reposted by Susan Dent MD FRCPC
Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ
December 18, 2024 at 8:22 PM
Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ
www.sciencedirect.com/science/arti...
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer
The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial…
www.sciencedirect.com
December 15, 2024 at 8:51 PM
www.sciencedirect.com/science/arti...
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!
Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!